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The impact of disease-causing defects is often not limited to the products of a mutated gene but,
thanks to interactions between the molecular components, may also affect other cellular functions,
resulting in potential comorbidity effects. By combining information on cellular interactions,
disease–gene associations, and population-level disease patterns extracted from Medicare data, we
ﬁnd statistically signiﬁcant correlations between the underlying structure of cellular networks and
diseasecomorbidity patterns inthe humanpopulation. Ourresultsindicatethat suchacombination
of population-level data and cellular network information could help build novel hypotheses about
disease mechanisms.
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Introduction
Most cellular functions are carried out by a complex network
of genes, proteins, and metabolites that interact through
biochemical and physical interactions (Gerstein et al, 2002;
Baraba ´si and Oltvai, 2004; Albert, 2005; Basso et al, 2005;
Almaas, 2007; Alon, 2007; Yildrim et al, 2007). Therefore,
disease-causing defects may initiate cascades of failures that
triggertheco-emergence ofmultiple diseasesina patient,such
asdiabetesand obesity. Yet, giventhe environmental, lifestyle,
or treatment-related factors that all contribute to comorbidity,
it is not obvious whether these cellular network-based
interdependencies manifest themselves at the individual
or at the population level. Discovering such systematic
correlations between cellular networks and disease patterns
could potentially open new avenues for understanding the
human interactome, and may help uncover hitherto unknown
disease mechanisms (Ergun et al, 2007; Loscalzo et al, 2007;
Braun et al, 2008).
The possibility that there may be systematic links between
hereditary diseases, thanks to their common genetic origins,
was postulated recently by Goh et al, who created a Human
Disease Network (HDN) by connecting all hereditary diseases
that share a disease-causing gene according to the Online
Mendelian Inheritance in Man (OMIM) database (Goh et al,
2007; Feldman et al, 2008). Although some of the diseases
connected in the HDN captured well-known comorbidity
patterns, the functional relevance of the links in the network
remains to be demonstrated, leaving open the question
whether most diseases connected in the HDN exhibit
signiﬁcant comorbidity. Interestingly, the most disconnected
disease class in the HDN is that of metabolic diseases.
However, Lee et al recently showed that metabolic diseases
can be also organized in a metabolic disease network if the
enzymes and their associated diseases are linked through
metabolic pathways (Lee et al, 2008). Most importantly, the
study found that metabolic diseases connected through shared
pathways tend to show signiﬁcant comorbidity, suggesting
that information encoded in the structure of the metabolic
network is ampliﬁed, becoming discernible at the population
level as comorbidity patterns.
Metabolic networks represent only one of the several
networks functionally relevant to our understanding of
cellular activity. Indeed, when it comes to cellular interactions
of potential importance to human diseases, we need to
consider protein–protein interaction (PPI) and coexpression
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shared genes. Therefore, earlier research raises an important
question: are the cellular-level relationships encoded by PPIs,
coexpression, and shared genes ampliﬁed at the population
level? That is, should we expect statistically signiﬁcant
comorbidity patterns for disease pairs that share a gene,
whose proteins interact, or whose genes show high coexpres-
sion patterns? To answer these questions, we analyzed the
large-scale comorbidity pattern extracted from the US Medi-
care claims database and the gene–disease association net-
work from OMIM (McCusick, 1998). We ﬁnd that cellular
interaction links indeed manifest themselves at the population
level,resulting in statisticallysigniﬁcant comorbidity patterns.
We quantify the relative magnitude of these correlations and
discuss the current difﬁculties in mapping population- and
cellular-level data into each other, as well as the beneﬁts of
such an approach toward elucidating disease mechanisms.
Results and discussion
The starting point of our study is the Medicare claims database
containing the diagnoses that Cij led to the hospitalization of
N¼13039018 elderly patients, each disease or condition
identiﬁed by an ICD-9-CM code. We denote the incidence of
disease i with Ii, and the number of patients who were
simultaneously diagnosed with diseases i and j with Cij.T h e
comorbid tendency between the two diseases can be quantiﬁed
using either the relative risk, RR¼Cij/Cij*, where Cij*¼IiIj/N
is the expectation value of Cij when the two diseases
are independent, or the f-correlation deﬁned as
f ¼ð NCij   IiIjÞ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
IiIjðN   IiÞðN   IjÞ
p
. When two diseases co-
occur more frequentlythanexpected bychance, wehave RR41
and f40. Note, however, that although RR and f are not
independent of each other, each carries unique biases that are
complementary. Therefore, we use both measures of comorbid-
ity to ensure the robustness of our ﬁndings (see Supplementary
i n f o r m a t i o n( S I )f o rf u r t h e rd e t a i l s ) .T h ed i s e a s e – g e n ea s s o c i a -
tions used in the study were obtained from the OMIM database,
which contains 44900 such associations as of October 2008.
Althoughthedisease–generecordisfarfromcomplete,OMIMis
currently the most complete repository of all known disease
genes and their associated disorders.
It is important to note that disease names used in the
Medicare database by the medical and the insurance commu-
nities (the ICD-9-CM scheme) and those used in the OMIM
database by geneticists are not identical. Therefore, we
enlisted a professional ICD-9-CM coder to manually map the
OMIM disease names into ICD-9-CM codes and established
connections between the genetic associations and the comor-
bidity measures (see Box 1 and SI sections S1 and S2 for more
detail). On account of the discrepancies in disease names and
the complex, hierarchical nature of the ICD-9-CM scheme, we
recognize that the mapping is not perfect, and may contain
debatable and occasionally erroneous ICD-9-CM-to-OMIM
correspondence. Therefore, we are providing the mapping
used by us in the SI, offering a chance for the community to
improve on it in future studies.
As OMIM comprises the set of hereditary or complex
diseases with validated gene–disease associations, it is
anticipated that only a subset of ICD-9-CM codes would
correspond to the diseases in the OMIM. Indeed, we ﬁnd that,
of the 412000 available ICD-9-CM codes, 763 unique ICD-9-
CM codes can be mapped to OMIM diseases. The fact that our
analysis is limited to 5% of possible diagnosis codes contained
in the Medicare database, could limit our population (patient)
coverage. We ﬁnd, however, that this is not the case: as
Figure 1A shows,90% of patients in the Medicaredatabase are
diagnosed with at least one disease whose ICD-9-CM code is
contained in our mapping to the OMIM database.
We use the following three quantities to capture the cellular
network-level relationship between diseases i and j,a s
illustrated in Figure 1B for the case of breast cancer (ICD-9-
CM 174) and cancer of bone and cartilage (ICD-9-CM 170.9,
see also SI):
(i) nij
g, the number of shared genes associated with both
diseases i and j, which quantiﬁes the potential common
genetic origin of the two diseases (Goh et al, 2007);
(ii) nij
p, the numberof PPIs between the proteins of diseases i
and j capturing the PPI network-level relationships between
them (Rual et al, 2005; Stelzl et al, 2005).
(iii)   rij, the average Pearson correlation of coexpression
betweenpairsofgenesfromeachdisease,capturingthedegree
to which the genes associated with the two diseases are
coexpressed (Ge et al, 2005).
The main question can be formulated as follows: does the
existence of these cellular-level links (i.e., nij
g40, nij
p40,
  rij40) between the two diseases increase the likelihood that
individuals simultaneously develop both conditions? We start
our investigation by measuring the Pearson correlation
between the cellular variables (nij
g, nij
p,   rij) and comorbidities
(RR and f) for 83924 disease pairs. Of these, 2239 pairs are
linked through either shared genes (nij
gX1) or PPIs (nij
pX1; 658
with shared genes, and 1873 with PPIs). In Figure 2A and
Table I we present the Pearson correlation coefﬁcients (PCCs)
between the comorbidity measures and the genetic variables.
Although n
g, in general, has the highest correlation with
comorbidity, we do observe positive PCC with all three
variables.
There are numerous factors that determine whether two
diseases co-occur in a patient, some of which are environ-
mental, lifestyle-related or treatment-induced. Our study
captures only the role of the cellular network on comorbidity.
The small magnitude of the correlations observed by us
suggests that the cellular network offers only a small
contribution to the observed comorbidity. Note, however, that
placing signiﬁcant emphasis on the magnitude of these
correlations is premature, as two known effects limit the
correlations observed by us. First, the magnitude of the
correlation is limited by the predictive power of speciﬁc
genetic mutations catalogued in the OMIM database, and the
likelihood of a patient developing a particular disease. Indeed,
it is known that genetic mutations result in an increase of at
most a few percentage points in the likelihood of an individual
developingaspeciﬁccomplexdisease(Loscalzo,2007)andthe
correlations observed byuscannot exceed theknowndisease–
gene correlations. Second, the correlations are further limited
by the noise in the mapping between the OMIM diseases and
the ICD-9-CM codes. As we noted, there is inherent ambiguity
both in the mapping as well as in the process of assigning a
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Each instance of such misdiagnosis or mapping ambiguity
decreases the magnitude of the observed correlations. There-
fore, at this point it is not the magnitude, but the statistical
signiﬁcance of the correlations that we can rely on. As
summarized in Table I, the observed correlations are
statistically signiﬁcant.
To quantify the degree of comorbidity caused by the
observedcorrelations,wemeasuredtheaveragecomorbidities
/RRS and /fS for disease pairs that are connected at the
cellular network level. Compared with the entire set of 83924
pairs of hereditary diseases considered in our study, we ﬁnd
(see Figure 2B; Table II) a two- to four-fold increase in the
average comorbidity in disease pairs that share genes (nij
gX1),
indicating that if a patient develops a particular disease
associated with a gene or multiple genes in the HDN, then they
have a two-fold higher chance of developing another disease
mapped to one or more common genes in the HDN, compared
with diseases that are not. An increased comorbidity is also
observed for disease pairs linked through PPIs (nij
pX1) and
high coexpression (  rijX0:5).
The observed correlations between the cellular links and
comorbiditiesraisearelatedquestion:woulddiseasepairsthat
aremoreinterconnectedthanothers(i.e.,havelargernij
g,nij
p,or
  rij) show higher comorbidity? To address this, in Figure 2C we
show that comorbidity increases rapidly with the number of
shared genes: sharing two or more genes (nij
gX2) results in
nearly a ﬁve-fold increase in comorbidity compared with
hereditarydisease pairsthat donot sharegenes.An increasein
comorbidity is observed with increasing nij
p and   rij as well
(Figure 2D and E), although the effect is weaker than that
observed for nij
g, which is not unexpected given the smaller
impactthatnij
pand   rij haveoncomorbidityincomparisonwithnij
g.
Note that the average comorbidity measured between all
pairs of diseases is 41 (Figure 2B), indicating that many
patients develop multiple disorders, whether or not the
speciﬁc diseases are linked at the cellular level. Such
correlations have been observed in other studies focused on
Box 1 Didactic Box
Incidence
Disease-gene association
Patient ID Diagnosis 1 Diagnosis 2 Diagnosis 3 ...
XXXXX
YYYYY
... ... ...
...
...
Diagnosis 10
...
...
...
Malignant neoplasm of female breast
(ICD-9-CM 174)
174
Malignant neoplasm of bone and cartilage
(ICD-9-CM 170.9)
170.9
174.1 170.9
... ... ...
Breast cancer
(OMIM 228)
ATM
PHB
ESR1
AR
BARD1
RAD51A BRCA2
BRCA1
Other
Genes
Chondrosarcoma (OMIM 316) 
Ewing sarcoma(OMIM 511)
Osteosarcoma (OMIM 1166)
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EXT1 TAF15
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Shared Genes
Schematic description of the procedure used to connect comorbidity (calculated in the Medicare Layer, top) and genetic associations (given in the OMIM Layer,
bottom) between a pair of diseases. Breast Cancer and Bone and Cartilage Cancer are treated as the example here, also presented in Figure 1B. In the Medicare
Layer (top), each disease is represented by an ICD-9-CM code, a widely used hierarchical disease diagnosis code system. The incidence Ii of each disease
(represented by a blue line) is found by counting patients in the Medicare database diagnosed with the corresponding ICD-9-CM code and its sub-level codes (i.e.
174.1 is also counted as an incidence of 174 for breast cancer), while the co-occurrence Cij (red line) of a disease pair is found by counting patients diagnosed with
both codes. The comorbidity measures RR and f can be calculated from these quantities and the total number of patients in the Medicare database (approximately
13 million). The associated genes of each disease are provided in the OMIM Layer (bottom, green lines). Because of differences in the disease-labeling schemes in
the Medicare (ICD-9-CM) and the OMIM databases (the codes are as given in Goh et al, 2007), we manually constructed a mapping between the two (grey lines).
See Supplementary information for detail.
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2009). These overall comorbidity patterns are not particularly
surprisingconsideringthattheMedicarepopulationis65years
of age or older, the age at which individuals do develop
multiple disorders. Thus, the overall comorbidity represents
the baseline against which we can assess the impact of the
genetic and cellular networks. It is reassuring, therefore, that
hereditary diseases that are linked in the HDN (and thus at the
cellular level) show comorbidity higher than the baseline
/RRS¼1.92±0.01 and /fS¼(1.84±0.02) 10
 3 observed for
the set of all disease pairs.
Despite the signiﬁcant increase in /RRS and /fS, there are
manydisease pairs that share genes yet fail to showsigniﬁcant
comorbidity. We hypothesize that this is, in part, because of
pleiotropy, which in this context means that different muta-
tions on the same gene can have different pathological effects
on a protein (Dudley et al, 2005), thereby predisposing an
individual to different disorders. In general, we expect that
diseasepairsassociatedwithmutationsonthesamefunctional
domain of the shared protein show higher comorbidity than
disease pairs whose mutations occur in different functional
domains. To test this hypothesis, we identiﬁed the functional
domains of disease-causing mutations on shared genes using
the Pfam database (Finn et al, 2006). In agreement with our
hypothesis, we ﬁnd higher /RRS and /fS, for disease pairs
whose mutations are on the same domain of the shared gene,
compared with disease pairs whose mutations are in distinct
functional domains (Figure 2B).
The observed correlations suggest that a combination of
disease data and cellular network information may assist us in
identifying new comorbidity patterns alongside their potential
genetic origin. Indeed, upon inspection of the 2239 disease
pairs that are genetically linked (i.e., nij
gX1o rnij
pX1), we ﬁnd
several disease pairs whose comorbidity patterns are already
well known to the medical community, such as diabetes and
obesity (Evans et al, 2002), or breast cancer and osteosarcoma
(Knowling and Basco, 1986). At the same time, due to the
aforementioned mismatch between disease names used by
clinicians (within the ICD-9 coding scheme) and by geneticists
(within the OMIM tabulation), several highly comorbid
disease pairs are readily anticipated (such as diabetes and
hypoglycemia, as hypoglycemia is a common side effect of the
treatment of diabetes) or cases in which one disease is a
broader version of the other (such as mononeuritis and
hereditary peripheral neuropathy). Such mapping limitations
notwithstanding, we ﬁnd several interesting disease pairs that
are linked at the cellular level and also show signiﬁcant
comorbidity. For example, consider Alzheimer’s disease (ICD-
9-CM 331) and myocardial infarction (ICD-9-CM 410.9), for
which earlier comorbidity studies were either inconclusive or
contradictory (Bursi et al, 2006). As Figure 3A shows, we not
only ﬁnd statistically signiﬁcant comorbidity (PE10
 5)
between the two, but the ﬁgure suggests that the shared ACE
and APOE genes may contribute to the observed effect.
Similarly, we observe signiﬁcant comorbidity (PE10
 148)
between autonomic nervous system disorder (ICD-9-CM
337.9) and carpal tunnel syndrome (ICD-9-CM 354,
Figure 3B). A known mechanism is L-chain amyloidosis,
which may affect the autonomic nervous system and causes
carpal tunnel syndromewhen the amyloid inﬁltrates the ﬂexor
retinaculum of the patient’s wrist (Haan and Peters, 1994).
Figure3B,however,suggests thataPPIbetweentheassociated
genes of each disorder may also play a role in the observed
effect. Although there may be additional possible physiologi-
cal or social explanations for some of the observed comorbid-
ities (see SI), the method described above has the potential to
offer new, testable hypotheses about the biological basis of
disease interrelationships. These examples were selected only
to demonstrate the potential of the combined investigation of
the network and population-level data in identifying poten-
tially interesting disease pairs worthy of further study. A more
detailed description of these disease pairs, along with the
complete list of the 2239 genetically linked disease pairs and
their genetic associations are provided in the SI.
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Figure 1 (A) The fraction of patients in the Medicare database diagnosed with
ICD-9-CMcodes mappedtoOMIMdiseases. Althoughthey representfewerthan
6% of all ICD-9-CM codes, 90% of the patients were diagnosed with at least one.
(B)Breastcancerandcancerofboneandcartilageofferanexampleofadisease
pair linked on the cellular-network level. They share two genes (CHEK2 and
TP53), and their proteins interact through 13 protein–protein interactions (green
lines). The average coexpression   r between the genes of each disease is 0.103.
Their comorbidity between the two diseases are RR¼8.69, indicating that the
number of patients who simultaneously develop both diseases shows a seven-
fold increase compared with random expectation, and f¼0.00813
(PE6 10
 71). (C) The functional domains of the TP53 protein. Breast cancer
and cancer of bone and cartilage shown also constitute a domain-sharing
disease pair: mutations on the TP53 protein associated with breast cancer and
cancer of bone and cartilage take place on the same P53 domain.
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treatment data on a large number of individuals offer
information useful to systems biology that can complement
the information from the well-established genomic studies.
Indeed, Medicare and insurance databases already collect the
health care history of millions of individuals, allowing us to
uncover the correlations in the occurrence of various diseases.
Inparallel,increasingknowledgeaboutthemolecularoriginof
disease indicates that many disorders are rooted in defects in
gene products that are part of the same cellular network,
raising the possibility that these diseases should co-occur in
the same individual. Admittedly, much of the currently
available network data are incomplete and probably noisy.
We may be approaching a tipping point, however, where we
have acquired sufﬁcient knowledge of human cellular net-
works to begin understanding the way a disturbance in the
networks may contribute to the development of a disease and
suggest potential disease-modifying factors.
To test the validity of this hypothesis, here we correlated
cellular level information for human cells, namely data on
shared genes, PPIs, and coexpression patterns, with comor-
bidity data obtained from the Medicare database. Despite the
aforementioned limitations of the mapping and the data
collection process, we found statistically signiﬁcant correla-
tions between cellular interactions and comorbidity patterns.
We also found that disease pairs with higher correlations tend
to be linked more strongly in the cellular network.
Although our work was mainly driven by the desire to
uncover evidence that cellular information is ampliﬁed in the
human population and thus can be detected from patient data,
our results point to the potential usefulness of our approach in
uncovering disease mechanisms. Indeed, we discuss two
disease pairs in which the network-based information offers a
plausible mechanism for statistically signiﬁcant comorbidity
patterns. These results suggest that Medicare and other
insurance databases could play an increasing role in future
studies of the systems biology of human cells and diseases.
Table II The average comorbidity of disease pairs satisfying various criteria,
quantifying the strength of the cellular and genetic links connecting the pairs
Number of pairs RR
(error)
f
(error)
All diseases 83924 1.92 (0.01) 1.84 (0.02) 10
 3
n
gX1 658 4.35 (0.60) 7.57 (0.96) 10
 3
n
pX1 1873 2.35 (0.16) 2.28 (0.23) 10
 3
  rX0:5 215 2.79 (0.32) 3.44 (0.82) 10
 3
n
gX1
Domain-sharing 182 5.98 (1.86) 9.77 (2.85) 10
 3
n
gX1
Non-domain-sharing 476 3.73 (0.38) 6.72 (0.84) 10
 3
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Figure 2 (A) The Pearson correlation between comorbidity and the three quantities (n
g, n
p,   r) that capture cellular-level links between diseases. See also Table I.
(B) Average comorbidity for disease pairs satisfying the cellular constraints discussed in the text. See also Table II. (C–E) Average comorbidity for disease pairs with
increasing values of n
g, n
p, and   r.
Table I The Pearson correlation between relative risk, f-correlation and
the three genetic variables (see Figure 2A)
Genetic
variables
Pearson correlation
with relative risk
Pearson correlation with
f-correlation
n
g 0.0469 (PE3.85 10
 4) 0.0902 (PE1.48 10
 4)
n
p 0.00948 (PE1.65 10
 2) 0.00941 (PE1.49 10
 2)
  r 0.0272 (PE1.07 10
 3) 0.0334 (PE3.41 10
 4)
All correlations are positive, with P-values shown in parentheses.
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Data sets
We used the HDN from Goh et al for disorder–gene associations (Goh
et al, 2007), updated based on the version of the Morbid Map from
OMIM at the time of the study. The most up-to-date version can be
found at http://www.ncbi.nlm.nih.gov/sites/entrez?db¼omim. The
PPI data were taken from Rual et al (2005) and Stelzl et al (2005). The
geneticcoexpressionlevelswerecalculatedonthebasisofanAffeymetrix
microarray data (Ge et al, 2005) (see www.affymetrix.com). Protein
domain information is available on UnitProt (http://www.uniprot.org/)
and Pfam (http://www.sanger.ac.uk/Software/Pfam/).
Estimating P-values and errors
The P-values for the PCCs shown in Figure 2A and Table I were
calculated by a Monte Carlo sampling method. We generate a
randomized sequence of the genetic variables and calculate its PCC
with comorbidity. After 2 million randomizations, the P-value is the
fraction of the total trials that resulted in a PCC that is larger thanwhat
was observed.
AsRRandf are monotonicallyincreasing functions of Cij, theirone-
sidedP-valueisequaltothesumofprobabilitiesthattheco-occurrence
Cij is larger than the actual value. It can be obtained using standard
computational software such as Mathematica (www.wolfram.com) by
approximatingthebinomialdistributiongeneratedfromthenumberof
patients N and Cij*¼Np¼IiIj/N as a Poisson distribution, and therefore
P ¼
X N
k¼Cij
expð C 
ijÞ ðC 
ijÞ
k
k!
The errors on the comorbidity values (Figure 2) were calculated using
the bootstrap method based on resampling (Efron, 1979; Newman and
Barkema, 1998).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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